Ada Wing Chi Yan

Ada Wing Chi Yan

Auto-generated profile, based on publicly available information

Ada Wing Chi Yan

Department of Mathematical and Geospatial Sciences, RMIT University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
TPThomas Peacock
Thomas Peacock
JBJonathan C. Brown
Jonathan C. Brown
JZJie Zhou
Jie Zhou
NTNazia Thakur
Nazia Thakur
KSKsenia Sukhova
Ksenia Sukhova
WBWendy S. Barclay
Wendy S. Barclay
The SARS-CoV-2 Omicron/BA.1 lineage emerged in late 2021 and rapidly displaced the Delta variant before being overtaken itself globally by, the Omicron/BA.2 lineage in early 2022. Here, we describe how Omicron BA.1 and BA.2 show a lower severity phenotype in a hamster model of pathogenicity which maps specifically to the spike gene. We further show that Omicron is attenuated in a lung cell line but replicates more rapidly, albeit to lower peak titres, in human primary nasal cells. This replication phenotype also maps to the spike gene. Omicron spike (including the emerging Omicron lineage BA.4) shows attenuated fusogenicity and a preference for cell entry via the endosomal route. We map the altered Omicron spike entry route and partially map the lower fusogenicity to the S2 domain, particularly the substitution N969K. Finally, we show that pseudovirus with Omicron spike, engineered in the S2 domain to confer a more Delta-like cell entry route retains the antigenic properties of Omicron. This shows a distinct separation between the genetic determinants of these two key Omicron phenotypes, raising the concerning possibility that future variants with large antigenic distance from currently circulating and vaccine strains will not necessarily display the lower intrinsic severity seen during Omicron infection.

1 June 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DGDaniel H. Goldhill
Daniel H. Goldhill
AYAda Yan
Ada Yan
RFRebecca Frise
Rebecca Frise
JZJie Zhou
Jie Zhou
JSJennifer Shelley
Jennifer Shelley
WBWendy S. Barclay
Wendy S. Barclay
Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical relevance of these mutations is unclear as the mutations have not been found in natural isolates and it is unknown whether viruses harbouring these mutations would replicate or transmit in vivo. Here, we infected ferrets with a mix of wild type p(H1N1) 2009 and corresponding favipiravir-resistant virus and tested for replication and transmission in the absence of drug. Favipiravir-resistant virus successfully infected ferrets and was transmitted by both contact transmission and respiratory droplet routes. However, sequencing revealed the mutation that conferred resistance, K229R, decreased in frequency over time within ferrets. Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R. We demonstrated that this fitness advantage of PA P653L in the background of our starting virus A/England/195/2009 was due to a maladapted PA in first wave isolates from the 2009 pandemic. We show there is no fitness advantage of P653L in more recent pH1N1 influenza A viruses. Therefore, whilst favipiravir-resistant virus can transmit in vivo, the likelihood that the resistance mutation is retained in the absence of drug pressure may vary depending on the genetic background of the starting viral strain.

15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YZYan Zhang
Yan Zhang
AYAda W.C. Yan
Ada W.C. Yan
LBLies Boelen
Lies Boelen
LHLinda Hadcocks
Linda Hadcocks
ASArafa Salam
Arafa Salam
BABecca Asquith
Becca Asquith
BACKGROUND. There is increasing evidence, in transgenic mice and in vitro, that inhibitory killer cell immunoglobulin-like receptors (iKIRs) can modulate T cell responses. Furthermore, we have previously shown that iKIRs are an important determinant of T cell–mediated control of chronic viral infection and that these results are consistent with an increase in the CD8+ T cell lifespan due to iKIR-ligand interactions. Here, we tested this prediction and investigated whether iKIRs affect T cell lifespan in humans in vivo. METHODS. We used stable isotope labeling with deuterated water to quantify memory CD8+ T cell survival in healthy individuals and patients with chronic viral infections. RESULTS. We showed that an individual’s iKIR-ligand genotype was a significant determinant of CD8+ T cell lifespan: in individuals with 2 iKIR-ligand gene pairs, memory CD8+ T cells survived, on average, for 125 days; in individuals with 4 iKIR-ligand gene pairs, the memory CD8+ T cell lifespan doubled to 250 days. Additionally, we showed that this survival advantage was independent of iKIR expression by the T cell of interest and, further, that the iKIR-ligand genotype altered the CD8+ and CD4+ T cell immune aging phenotype. CONCLUSIONS. Together, these data reveal an unexpectedly large effect of iKIR genotype on T cell survival. FUNDING. Wellcome Trust; Medical Research Council; EU Horizon 2020; EU FP7; Leukemia and Lymphoma Research; National Institute of Health Research (NIHR) Imperial Biomedical Research Centre; Imperial College Research Fellowship; National Institutes of Health; Jefferiss Trust.

9 August 2023 in Journal of The Royal Society Interface
Verified
Journal Article
Open access
CMClare P. McCormack
Clare P. McCormack
AYAda W. C. Yan
Ada W. C. Yan
JBJonathan C. Brown
Jonathan C. Brown
KSKsenia Sukhova
Ksenia Sukhova
TPThomas Peacock
Thomas Peacock
IDIlaria Dorigatti
Ilaria Dorigatti
We use viral kinetic models fitted to viral load data from in vitro studies to explain why the SARS-CoV-2 Omicron variant replicates faster than the Delta variant in nasal cells, but slower than Delta in lung cells, which could explain Omicron's higher transmission potential and lower severity. We find that in both nasal and lung cells, viral infectivity is higher for Omicron but the virus production rate is higher for Delta, with an estimated approximately 200-fold increase in infectivity and 100-fold decrease in virus production when comparing Omicron with Delta in nasal cells. However, the differences are unequal between cell types, and ultimately lead to the basic reproduction number and growth rate being higher for Omicron in nasal cells, and higher for Delta in lung cells. In nasal cells, Omicron alone can enter via a TMPRSS2-independent pathway, but it is primarily increased efficiency of TMPRSS2-dependent entry which accounts for Omicron's increased activity. This work paves the way for using within-host mathematical models to understand the transmission potential and severity of future variants.

17 January 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
AYAda W C Yan
Ada W C Yan
SZSophie G Zaloumis
Sophie G Zaloumis
JSJulie A Simpson
Julie A Simpson
JMJames McCaw
James McCaw
Laboratory models are often used to understand the interaction of related pathogens via host immunity. For example, recent experiments where ferrets were exposed to two influenza strains within a short period of time have shown how the effects of cross-immunity vary with the time between exposures and the specific strains used. On the other hand, studies of the workings of different arms of the immune response, and their relative importance, typically use experiments involving a single infection. However, inferring the relative importance of different immune components from this type of data is challenging. Using simulations and mathematical modelling, here we investigate whether the sequential infection experiment design can be used not only to determine immune components contributing to cross-protection, but also to gain insight into the immune response during a single infection. We show that virological data from sequential infection experiments can be used to accurately extract the timing and extent of cross-protection. Moreover, the broad immune components responsible for such cross-protection can be determined. Such data can also be used to infer the timing and strength of some immune components in controlling a primary infection, even in the absence of serological data. By contrast, single infection data cannot be used to reliably recover this information. Hence, sequential infection data enhances our understanding of the mechanisms underlying the control and resolution of infection, and generates new insight into how previous exposure influences the time course of a subsequent infection. The resolution of an influenza infection requires different components of the immune response to work together. Despite recent advances in mathematical modelling, we do not well understand how much each broad immune component contributes to this process at a given time. In this study, we show that laboratory data on the amount of virus over the course of a single infection is insufficient for inferring the contribution of each broad immune component. However, if the animals are exposed to two different virus strains with only days separating exposures, then the timing and strength of protection provided by the first infection against the second provides crucial additional information. We show how mathematical models can be used to recover the timing and strength of each immune component, thus enhancing our understanding of how an infection is controlled, and how a previous exposure changes the time course of a subsequent infection.

1 September 2018 in Mathematical Biosciences
Verified
Journal Article
Closed access
AYAda W.C. Yan
Ada W.C. Yan
ABAndrew J. Black
Andrew J. Black
JMJames McCaw
James McCaw
NRNicolas Rebuli
Nicolas Rebuli
JRJoshua V. Ross
Joshua V. Ross
RHRoslyn I Hickson
Roslyn I Hickson